 |
|
|
| |
SUMMARY OF COVID-RELATED IMPACT ON
CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING (CAB + RPV LA) DOSING ACROSS THE SIX ONGOING
GLOBAL PHASE IIB and III CLINICAL TRIALS
|
| |
| |
IDWeek 2020 Oct 21-25 virtual
Reported by Jules Levin
Maggie Czarnogorski, MD, MPH1; Ronald D'Amico, DO, MSc1; Paul Benn, MB ChB, FRCP2;
Cindy McCoig, MD3; Sandy Griffith, PharmD1; Kris Hudson, PhD1; Ken Sutton, MS1;
Conn Harrington, BA1; Sterling Wu, PhD4; Will Williams, BS4; Kai Hove, MRes5;
Carlos Martín Espanol, MSc5; Jane Fricker, BS5; Parul Patel, PharmD1; David Margolis, MD1
1ViiV Healthcare, Research Triangle Park, NC, USA; 2ViiV Healthcare, Brentford, UK; 3ViiV Healthcare, Madrid, Spain;
4GlaxoSmithKline, Collegeville, PA, USA; 5GlaxoSmithKline, London, UK
|
| |
|
|
|
|
|
